Apnimed Reports Q3 2026 Financial Results & Pipeline Update

Health

Earnings
IPO:
Jul 31, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., USA - Apnimed, Inc. (Nasdaq: APMD), a late-stage clinical pharmaceutical company focused on novel oral therapies for sleep-related breathing diseases, reported its financial results for the third quarter ended September 30, 2026, and provided a corporate update.
... Read on — Members only
About Apnimed, Inc.
We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA).

















